relapsed
Showing 1 - 25 of 7,775
Relapsed Adult ALL, Relapsed Adult AML Trial in Changchun (Plerixafor)
Active, not recruiting
- Relapsed Adult ALL
- Relapsed Adult AML
-
Changchun, Jilin, ChinaFirst Hospital of Jilin University
Nov 19, 2023
Refractory Cancer, Relapsed Cancer Trial in Weston (Drug Sensitivity Test (DST))
Not yet recruiting
- Refractory Cancer
- Relapsed Cancer
- Drug Sensitivity Test (DST)
-
Weston, FloridaLerner College of Medicine: Cleveland Clinic Florida
Sep 1, 2023
Relapsed and/or Refractory Multiple Myeloma Trial in Köln (BMS-986453, Fludarabine, Cyclophosphamide)
Not yet recruiting
- Relapsed and/or Refractory Multiple Myeloma
- BMS-986453
- +2 more
-
Köln, GermanyLocal Institution - 0017
Dec 4, 2023
Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small
Recruiting
- Relapsed or Refractory CD19+ B-cell Lymphoma
- +2 more
- TBI-2001
- +2 more
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Jul 26, 2023
PET-CT Imaging in Relapsed/Refractory Acute Leukemias
Not yet recruiting
- B Cell
- +2 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Aug 4, 2023
Relapsed/Refractory Multiple Myeloma Trial in Suzhou (ICI201)
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
-
Suzhou, Jiangsu, ChinaFirst Affiliated Hospital, Soochow University
Jul 31, 2023
Relapsed or Refractory Multiple Myeloma Trial (Forimtamig, Carfilzomib, Daratumumab)
Not yet recruiting
- Relapsed or Refractory Multiple Myeloma
- Forimtamig
- +2 more
- (no location specified)
Sep 20, 2023
Relapsed/Refractory Large B-cell Lymphoma Trial (KITE-197, Cyclophosphamide, Fludarabine)
Not yet recruiting
- Relapsed/Refractory Large B-cell Lymphoma
- KITE-197
- +2 more
- (no location specified)
Oct 6, 2023
Acute Myeloid Leukemia Trial (MCBC regimen, Bu/Cy regimen)
Not yet recruiting
- Acute Myeloid Leukemia
- MCBC regimen
- Bu/Cy regimen
- (no location specified)
Nov 13, 2023
Relapsed or Refractory Lymphomas, Advanced Solid Tumor Trial in Los Alamitos (LP-284)
Not yet recruiting
- Relapsed or Refractory Lymphomas
- Advanced Solid Tumor
-
Los Alamitos, CaliforniaCancer and Blood Specialty Clinic
Nov 9, 2023
Relapsed and Refractory Multiple Myeloma Trial in Pittsburgh (Mezigdomide, Ixazomib, Dexamethasone)
Not yet recruiting
- Relapsed and Refractory Multiple Myeloma
- Mezigdomide
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Sep 15, 2023
Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)
Active, not recruiting
- Relapsed or Refractory Diffuse Large B-cell Lymphoma
- BEBT-908 for injection
-
Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Oct 8, 2023
CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,
Not yet recruiting
- CD19-positive Relapsed or Refractory B-cell Malignancies
- UTAA09 cells for infusion
- +2 more
-
Hefei, Anhui, ChinaThe First Affiliated Hospital of USTC (AnHui Provincial Hospital
Oct 13, 2023
Relapsed or Refractory B-cell Lymphoma Trial in Guangzhou (infusion of JY231 injection)
Recruiting
- Relapsed or Refractory B-cell Lymphoma
- infusion of JY231 injection
-
Guangzhou, Guangdong, ChinaGuangdong Second Provincial General Hospital
Sep 17, 2023
Relapsed/Refractory B-Cell Lymphoma Trial (FT522, Rituximab, Cyclophosphamide)
Not yet recruiting
- Relapsed/Refractory B-Cell Lymphoma
- FT522
- +4 more
- (no location specified)
Jul 10, 2023
Refractory/Relapsed Autoimmune Hemolytic Anemia Trial in Tianjin (Zanubrutinib)
Not yet recruiting
- Refractory/Relapsed Autoimmune Hemolytic Anemia
-
Tianjin, Tianjin, ChinaRegenerative Medicine Center
Aug 27, 2023
Relapsed or Refractory Hodgkin Lymphoma Trial in Beijing (SHR2554+ SHR1701, SHR-1701)
Recruiting
- Relapsed or Refractory Hodgkin Lymphoma
- SHR2554+ SHR1701
- SHR-1701
-
Beijing, Beijing, ChinaHan wei dong
Jun 14, 2023
Relapsed/Refractory Multiple Myeloma, Amyloid Light-chain Amyloidosis Trial (SAR445514)
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
- Amyloid Light-chain Amyloidosis
- (no location specified)
Apr 20, 2023
Relapsed or Refractory B-cell Lymphoma Trial (Relmacabtagene Autoleucel Injection)
Not yet recruiting
- Relapsed or Refractory B-cell Lymphoma
- Relmacabtagene Autoleucel Injection
- (no location specified)
Apr 13, 2023
Relapsed or Refractory T-cell Lymphomas Trial in Sendai-shi (BMS-986369)
Not yet recruiting
- Relapsed or Refractory T-cell Lymphomas
-
Sendai-shi, Miyagi, JapanLocal Institution - 0001
Sep 12, 2023
Relapsed or Refractory Multiple Myeloma Trial in Tianjin (YTS104 Cells injection)
Not yet recruiting
- Relapsed or Refractory Multiple Myeloma
- YTS104 Cells injection
-
Tianjin, Tianjin, ChinaInstitute of Hematology & Blood Diseases Hospital
Jun 13, 2023
Relapsed/Refractory Multiple Myeloma Trial in Benowa (ISB 2001)
Not yet recruiting
- Relapsed/Refractory Multiple Myeloma
- ISB 2001
-
Benowa, Queensland, AustraliaPindara Private Hospital
May 18, 2023
Relapsed or Refractory (R/R) Primary CNS Lymphoma Trial in Nanjing (thiotepa combined with pomalidomide)
Recruiting
- Relapsed or Refractory (R/R) Primary Central Nervous System Lymphoma
- thiotepa combined with pomalidomide
-
Nanjing, Jiangsu, ChinaJiangsu Province People's Hospital.
Jun 27, 2023